Johnson & Johnson's Fiscal Year is From January To December - All Figures are in USD, Billions.
The item "Capital-Expenditures" stands at 5.14 Billion United States Dollars for the trailing twelve months (TTM) period ending 09/30/2025, the lowest value since 09/30/2024.
Johnson & Johnson's third quarter result of 0.788 Billion USD for the item "Capital Expenditures" represents a decrease of -43.63 percent compared to it's second quarter result.
Also, Johnson & Johnson's third quarter result of 0.788 Billion USD for the item "Capital Expenditures" represents a decrease of -65.42 percent compared to it's third quarter result of last year.
Looking again at the trailing twelve months series (TTM), Johnson & Johnson's third quarter result of 5.14 Billion USD for the item "Capital Expenditures" represents a decrease of -22.49 percent compared to it's second quarter result.
Regarding the One-Year-Change of the series, the current value constitutes a decrease of -9.04 percent compared to the value the year prior.
The 1 year change in percent is -9.04.
The 3 year change in percent is 33.96.
The 5 year change in percent is 56.52.
The 10 year change in percent is 43.06.
| Logo | Name | Market Cap (USD) |
|---|---|---|
![]() | Eli Lilly and Company - Capital Expenditures | 905,699,262,464.00 |
![]() | AbbVie Inc - Capital Expenditures | 399,570,305,024.00 |
![]() | Roche Holding AG - Capital Expenditures | 317,433,206,677.55 |
![]() | AstraZeneca PLC - Capital Expenditures | 280,205,508,085.11 |
![]() | Novartis AG - Capital Expenditures | 255,096,620,580.91 |